1. Home
  2. NKTX vs HUMA Comparison

NKTX vs HUMA Comparison

Compare NKTX & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.93

Market Cap

198.2M

Sector

Health Care

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$0.71

Market Cap

191.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTX
HUMA
Founded
2015
2004
Country
United States
United States
Employees
N/A
184
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.2M
191.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NKTX
HUMA
Price
$2.93
$0.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$11.33
$6.19
AVG Volume (30 Days)
794.4K
18.7M
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
11.88
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$444.16
Revenue Next Year
N/A
$248.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$0.55
52 Week High
$3.72
$2.84

Technical Indicators

Market Signals
Indicator
NKTX
HUMA
Relative Strength Index (RSI) 48.54 38.43
Support Level $2.50 $0.60
Resistance Level $3.29 $1.26
Average True Range (ATR) 0.31 0.10
MACD 0.03 -0.01
Stochastic Oscillator 22.91 30.68

Price Performance

Historical Comparison
NKTX
HUMA

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: